Aflibercept Arm for Macular Edema
Phase-Based Progress Estimates
Effectiveness
Safety
Macular Edema+2 More
Iluvien 0.19 MG Drug Implant - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial is testing whether or not a new treatment for DME is better than the standard treatment. It will enroll patients who have not had any DME treatments for the past 12 months, and compare the new treatment to the standard treatment.
Eligible Conditions
- Macular Edema
- Diabetic Macular Edema (DME)
Treatment Effectiveness
Effectiveness Progress
This is further along than 93% of similar trials
Other trials for Macular Edema
Study Objectives
1 Primary Ā· 6 Secondary Ā· Reporting Duration: At 18 months
At 18 months
Mean change from baseline in the National Eye Institute Visual Function Questionnaire (NEI VFQ-25) composite score and subscale scores
Proportion of subjects with 15, 10 and 5 letter (ETDRS) gains from baseline
Baseline to 18 months
Area under the curve (AUC) of Best Corrected Visual Acuity (BCVA)
Area under the curve (AUC) of Center Subfield Thickness (CST)
Mean change from baseline in Center Subfield Thickness (CST)
Safety Outcome Endpoints: The incidence and severity of treatment-related adverse events
The mean total number of supplemental aflibercept injections needed during the study
Trial Safety
Safety Progress
This is further along than 85% of similar trials
Other trials for Macular Edema
Trial Design
2 Treatment Groups
Aflibercept Arm
1 of 2
ILUVIEN Arm
1 of 2
Active Control
300 Total Participants Ā· 2 Treatment Groups
Primary Treatment: Aflibercept Arm Ā· No Placebo Group Ā· Phase 4
Aflibercept Arm
Drug
ActiveComparator Group Ā· 1 Intervention: Aflibercept Ā· Intervention Types: DrugILUVIEN ArmActiveComparator Group Ā· 2 Interventions: Iluvien 0.19 MG Drug Implant, Aflibercept Ā· Intervention Types: Drug, Drug
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at 18 months
Who is running the clinical trial?
Alimera SciencesLead Sponsor
10 Previous Clinical Trials
1,909 Total Patients Enrolled
8 Trials studying Macular Edema
1,886 Patients Enrolled for Macular Edema
Samer Kaba, MDStudy ChairAlimera Sciences, Inc.
Eligibility Criteria
Age 18+ Ā· All Participants Ā· 3 Total Inclusion Criteria
Mark āyesā if the following statements are true for you:BCVA of ā¤80 ETDRS Letters and ā„35 ETDRS Letters in the study eye at Screening Visit.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments